eMedicine Specialties > Pediatrics: General Medicine > Parasitology

Cysticercosis

Author: Delaram Ghadishah, MD, FACEP, Staff Physician, Encino Hospital Emergency Department
Coauthor(s): Michael James Burns, MD, FACEP, FACP, Health Science Clinical Professor, Department of Emergency Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of California Irvine School of Medicine
Contributor Information and Disclosures

Updated: Oct 7, 2009

Introduction

Background

Cysticercosis, a tissue infection that involves larval cysts of the cestode Taenia solium (the human pork tapeworm), results from the ingestion of food (especially vegetables) and water contaminated with human feces that contain T solium eggs.

Although infections with Taenia tapeworm cysts may involve many parts of the body, the most common site of severe symptomatic infection is the CNS.

Cysticercosis life cycle. Image courtesy of the C...

Cysticercosis life cycle. Image courtesy of the Centers for Disease Control and Prevention.

Cysticercosis life cycle. Image courtesy of the C...

Cysticercosis life cycle. Image courtesy of the Centers for Disease Control and Prevention.


Neurocysticercosis, the most common parasitic disease of the CNS, is the most common cause of adult-onset epilepsy in many of the countries where the infection is endemic.

Pathophysiology

Cysticercosis, the intermediate form of T solium infection, is predominantly acquired by ingesting food or water contaminated with T solium eggs. Additionally, autoinfection may occur by means of fecal-oral contact and, theoretically, by reverse peristalsis in the small intestines of individuals infected with adult T solium worms.

In the stomach, oncospheres are liberated following digestion of the eggs' coats. Oncospheres invade and cross the intestinal wall, enter the bloodstream, and then migrate to and lodge in tissues throughout the body, where they produce small (0.2-0.5 cm) fluid-filled bladders containing a single juvenile-stage parasite (protoscolex).

Although the cysticerci may infect any organ of the body (most often the eye, skeletal muscle, and CNS), serious disease almost exclusively involves the CNS and heart.

Oncospheres that invade the brain may lodge in the brain parenchyma, subarachnoid space, ventricular space, or spinal cord. Cysticerci develop after 2 months and may or may not stimulate an appreciable inflammatory response.

In the brain parenchyma, cysticerci form a thin capsule of fibrous tissue that thickens with time. After several years, the parasite dies or is killed and is replaced by an astroglial and fibrous tissue granuloma that becomes calcified. The number of cysticerci present ranges from one to several hundred.

Cysts that grow in the sylvian fissure and in the subarachnoid space at the base of the skull may enlarge to 10-15 cm in diameter. Meningeal and spinal cord cysticercosis occurs if the oncospheres enter via the choroid plexus and hatch in the arachnoid membranes along the neural axis.

Cysts that develop in the subarachnoid space may cause an inflammatory response. Subsequent fibrosis of the arachnoid membranes may interfere with normal cerebral spinal fluid (CSF) resorption, resulting in hydrocephalus. Fourth ventricle cysts can create a subacute hydrocephalus via a valve-and-ball mechanism. However, head movement can suddenly increase the intracranial pressure (ICP).

With the exception of massive or obstructive disease, the cystic stages of most tapeworms do not provoke a strong immunologic response while they remain alive and intact. However, once the cysts die, the immune system recognizes them as foreign, and a vigorous immunologic response ensues. Seizures, hydrocephalus, blindness, strokes, meningitis, encephalitis, irreversible brain damage, myositis, and myocarditis may occur. Death may subsequently occur.

Frequency

United States

Cysticercosis is not endemic to the United States, although domestic transmission has been documented from recent immigrants to the United States from highly endemic areas.1 Historically, rates significantly decreased in the 1970s.

Since the 1970s, the number of cases of neurocysticercosis in the United States has increased, mainly because of the large number of immigrants from areas with endemic disease, such as Mexico, Central and South America, Africa, Asia, Spain, and Portugal. Americans without a travel history to such areas have developed neurocysticercosis, mainly because of exposure to a cohabitant with a T solium infection.

Disease is prevalent in areas with low socioeconomic status and poor hygiene and sanitation.

International

An accurate estimation of the prevalence of cysticercosis is difficult because of the high prevalence of asymptomatic individuals. Overall, more than 2 million people are estimated to have adult tapeworm infection, and many more are infected with cysticercoids. Disease is prevalent in areas with poor hygiene and sanitation.

Cysticercosis is endemic throughout Latin American, although it is rare in Chile, Argentina, and Uruguay.

Cysticercosis is absent in Arabic regions of Asia and Africa but is found in areas where pigs live in close proximity to humans. In Europe, cysticercosis is still endemic in Spain, Portugal, and some Eastern European countries but is rare in most other countries.

Mortality/Morbidity

Worldwide, an estimated 50,000 people die from cysticercosis each year because of CNS or cardiac complications.

Race

No racial predilection for cysticercosis is known.

Sex

The prevalence does not differ according to sex.

Age

No known age-based differences in the frequency of cysticercosis have been reported.

Clinical

History

  • The clinical presentation of cysticercosis depends on the number, location, and stage of the lesions present, as well as the host immune response.
  • In general, the diagnosis of neurocysticercosis should be considered in any individual who is from or has traveled to an area where T solium is endemic and who has new-onset partial seizures (with or without secondary generalization), behavioral disturbances, confusion, stupor, cognitive impairment, or signs of increased intracranial pressure (ICP).
  • Seizures are the presenting symptom in more than 70% of cases. The seizures frequently begin as simple or complex partial seizures but become generalized in 80% of cases.
  • Parenchymal disease causes seizures and focal neurologic deficits.
  • Headache, vertigo, vomiting, papilledema, an altered level of consciousness, and gait disturbances may be present in patients with meningeal cysticercosis.
  • Spinal neurocysticercosis can cause spinal cord compression, nerve root pain, transverse myelitis, or meningitis.
  • Intraventricular neurocysticercosis (5-10% of all cases) is associated with hydrocephalus and acute, subacute, or intermittent signs of increased ICP without localizing signs.
    • The lateral ventricles are less likely to become obstructed, whereas the fourth ventricle most commonly becomes obstructed.
    • Hydrocephalus develops from the intense and widespread immune response in the subarachnoid space.
  • Ocular cysticercosis may decrease visual acuity because of retinal detachment, iridocyclitis, or floating cysticerci in the vitreous.
  • Heavy infections in skeletal or heart muscle may result in myositis or carditis, respectively.
  • Rarely, cysticerci may obstruct small terminal arteries or cause a vasculitis, leading to a cerebral infarction.
  • Children with an acute infection that is massive may present with signs and symptoms of fulminant encephalitis.
  • Intellectual deterioration due to extensive frontal lobe disease may simulate dementia or parkinsonism.
  • Chronic basilar meningitis is associated with many forms of neurocysticercosis. In addition to signs of meningeal irritation, increased ICP due to inflammation, edema, or an obstructing cyst may be present.

Physical

  • Findings vary depending on the number, location, and local effects of cysticerci, as well as on the host response.
  • In general, neurologic deficits, seizures, and subcutaneous or ocular cysts may be present.
  • Cysts may be palpable under the skin.
  • The features of the history assist in focusing the physical examination.

Causes

  • Cysticercosis is caused by the ingestion of T solium eggs. The human is the only definitive host of the adult pork tapeworm, which lives in the human intestinal tract and lays eggs that are shed in human feces. In the normal life cycle of the parasite, eggs shed in human feces are ingested by pigs, which then develop cysticerci in muscle tissue. Human infection with the adult tapeworm develops in people who ingest raw or poorly cooked pork that contains cysticerci. Note that human ingestion of pork does not result in the development of cysticercosis.
  • Contamination of water, fruits, and vegetables by human feces that contain eggs is usually the result of poor sanitation.
  • Untreated, adult T solium worms may cause autoinfection by means of fecal-oral ingestion and reverse peristalsis, but this is believed to be very uncommon.

More on Cysticercosis

Overview: Cysticercosis
Differential Diagnoses & Workup: Cysticercosis
Treatment & Medication: Cysticercosis
Follow-up: Cysticercosis
Multimedia: Cysticercosis
References

References

  1. Schantz PM, Moore AC, Munoz JL, et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med. Sep 3 1992;327(10):692-5. [Medline].

  2. Krumholz A, Wiebe S, Gronseth G, et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. Nov 20 2007;69(21):1996-2007. [Medline].

  3. AAP Committee on Infectious Diseases. Cysticercosis. In: AAP 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. 2000:560-2.

  4. Abuseir S, Kuhne M, Schnieder T, Klein G, Epe C. Evaluation of a serological method for the detection of Taenia saginata cysticercosis using serum and meat juice samples. Parasitol Res. Jun 2007;101(1):131-7. [Medline].

  5. Ahmad FU, Sharma BS. Treatment of intramedullary spinal cysticercosis: report of 2 cases and review of literature. Surg Neurol. Jan 2007;67(1):74-7; discussion 77. [Medline].

  6. Alonso-Trujillo J, Rivera-Montoya I, Rodriguez-Sosa M, Terrazas LI. Nitric oxide contributes to host resistance against experimental Taenia crassiceps cysticercosis. Parasitol Res. Jan 6 2007;[Medline].

  7. Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology. Dec 26 2006;67(12 Suppl 4):S19-22. [Medline].

  8. Blanton R. Cysticercosis. In: Nelson Textbook of Pediatrics. 16th ed. Philadelphia, PA: WB Saunders; 2000:1078-9.

  9. Cohn-Zurita F, Guinto-Balanzar G, Perez-Cerdan H. [Neurocysticercosis associated with pituitary adenoma. Case report and literature review.]. Cir Cir. Jan-Feb 2006;74(1):47-9. [Medline].

  10. Evans CAW, Garcia HH, Gilman RH. Cysticercosis. In: Hunter's Tropical Medicine and Emerging Infectious Diseases. Philadelphia, PA: WB Saunders; 2000:862-6.

  11. Facanha MC. [Cysticercosis' admissions in public health hospitals: Ceara State distribuition]. Rev Soc Bras Med Trop. Sep-Oct 2006;39(5):484-7. [Medline].

  12. Galan-Puchades MT, Fuentes MV. The specificity of the electroimmunotransfer blot assay for Taenia solium cysticercosis. Clin Microbiol Infect. Jan 2007;13(1):111-2; author reply 112. [Medline].

  13. Garcia HH, Cancrini G, Bartalesi F, et al. Evaluation of immunodiagnostics for toxocarosis in experimental porcine cysticercosis. Trop Med Int Health. Jan 2007;12(1):107-10. [Medline].

  14. Garcia HH, Del Brutto OH. Taenia solium cysticercosis. Infect Dis Clin North Am. Mar 2000;14(1):97-119, ix. [Medline].

  15. Geysen D, Kanobana K, Victor B, et al. Validation of meat inspection results for Taenia saginata cysticercosis by PCR-restriction fragment length polymorphism. J Food Prot. Jan 2007;70(1):236-40. [Medline].

  16. Goetz CG, Pappert EJ. Textbook of Clinical Neurology. Philadelphia, PA: WB Saunders; 1999.

  17. Ishida MM, Peralta RH, Livramento JA, et al. Serodiagnosis of neurocysticercosis in patients with epileptic seizure using ELISA and immunoblot assay. Rev Inst Med Trop Sao Paulo. Nov-Dec 2006;48(6):343-6. [Medline].

  18. King CH. Cestode infections. In: Cecil Textbook of Medicine. ed. 2000:1975-8.

  19. King CH. Cestodes (tapeworms). In: Mandell's Principles and Practice of Infectious Diseases. 5th ed. New York, NY: Churchill Livingstone; 2000:2956-62.

  20. Kumar A, Pushker N, Bajaj MS, et al. Unifocal, subconjunctival twin cysticercosis cysts. J Pediatr Ophthalmol Strabismus. Jan-Feb 2007;44(1):55-6. [Medline].

  21. Li T, Craig PS, Ito A, et al. Taeniasis/cysticercosis in a Tibetan population in Sichuan Province, China. Acta Trop. Dec 2006;100(3):223-231. [Medline].

  22. Mahajan D, Khurana N, Setia N. Coexistence of salivary gland cysticercosis with squamous cell carcinoma of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jan 11 2007;[Medline].

  23. Manfredi MT, Ghirardelli R, Zanzani S. [Cysticercus tenuicollis infection in a goat farm]. Parassitologia. Sep 2006;48(3):433-6. [Medline].

  24. Proano JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001;345(12):879-85. [Medline][Full Text].

  25. Rajshekhar V, Raghava MV, Prabhakaran V, et al. Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. Neurology. Dec 26 2006;67(12):2135-9. [Medline].

  26. Rodriguez-Hidalgo R, Benitez-Ortiz W, Praet N, et al. Taeniasis-cysticercosis in Southern Ecuador: assessment of infection status using multiple laboratory diagnostic tools. Mem Inst Oswaldo Cruz. Nov 2006;101(7):779-82. [Medline].

  27. Sandes AR, Mouzinho A, Valente P. Orbital cysticercosis: diagnosis and treatment controversies. Pediatr Infect Dis J. Feb 2007;26(2):180-1. [Medline].

  28. Sciutto E, Rosas G, Hernandez M, et al. Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine. Feb 9 2007;25(8):1368-78. [Medline].

  29. Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. 2003;22(3):268-72. [Medline].

  30. Singhi P, Singhi S. Neurocysticercosis in children. Indian J Pediatr. May 2009;76(5):537-45. [Medline].

  31. Verulashvili I, Glonti L, Miminoshvili D, et al. [Basal Ganglia calcification: clinical manifestations and diagnostic evaluation.]. Georgian Med News. Nov 2006;39-43. [Medline].

  32. Zheng Y, Cai X, Luo X, et al. Characterization of a new gene (SLC10) with a spliced leader from Taenia solium. Vet J. Feb 2 2007;[Medline].

Further Reading

Keywords

cysticercosis, neurocysticercosis, giant cysticercosis, cysticercus cellulosae, cysticercus racemosus, adult-onset epilepsy, cysticerci, tapeworm infection, cysticercoids, neurocysticercosis, cysticerci, hydrocephalus, parkinsonism, treatment, diagnosis

Contributor Information and Disclosures

Author

Delaram Ghadishah, MD, FACEP, Staff Physician, Encino Hospital Emergency Department
Delaram Ghadishah, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Michael James Burns, MD, FACEP, FACP, Health Science Clinical Professor, Department of Emergency Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of California Irvine School of Medicine
Michael James Burns, MD, FACEP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American College of Physicians, American Society of Tropical Medicine and Hygiene, California Medical Association, Infectious Diseases Society of America, Phi Beta Kappa, Royal Society of Tropical Medicine and Hygiene, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Glenn J Fennelly, MD, MPH, Director, Division of Pediatric Infectious Diseases, Jacobi Medical Center; Associate Professor, Department of Pediatrics, Albert Einstein College of Medicine
Glenn J Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Martin Weisse, MD, Program Director, Associate Professor, Department of Pediatrics, West Virginia University
Martin Weisse, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; sanofi pasteur Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.